CEL-SCI Reports March 2014 Is Record Month for Patient Enrollment in Phase III Head and Neck Cancer Trial
CEL-SCI Corporation today announced that during the month of March the Company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global Phase III head and neck cancer trial. This marks the largest number of patients enrolled in the Company’s trial with its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in any month to date.
View full press release